Poland· PL-100474555
Radelumin 1300 MBq/ml
A psma-1007 18f product containing psma-1007 (18f) solutio iniectabilis, registered in Poland by Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Psma-1007 18f is registered in 4 of 19 countries.
Countries holding a registration under ATC V09IX17 (psma-1007 18f), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Psma-1007 18f · ATC V09IX17
4 / 19 countries
- Belgiumprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- PSMA-1007 (18F) solutio iniectabilis
- Manufacturer
- Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
- Country
- Poland (PL)
- ATC code
- V09IX17
- ATC class
- PSMA-1007 18F
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991564339
- gtin05909991564346
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V09IX17
Psma-1007 18f, as other registers publish it.
- Switzerland18F-PSMA-1007 ZRP ≥ 40 MBq / mL, InjektionslösungUniversitätsspital Zürich
- BelgiumRadelumin 1300 MBq/mlAbx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien
- NetherlandsRadelumin 1300 MBq/ml oplossing voor injectieABX advanced biochemical compounds, Biomedizinische Forschungsreagenzien GmbH
- SwitzerlandRadelumin 200 - 4500 MBq/ml, InjektionslösungPosimed Radiopharm AG
- BelgiumRadelumin 2000 MBq/mlAbx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien
- PolandRadelumin 2000 MBq/mlAbx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
- NetherlandsRadelumin 2000 MBq/ml oplossing voor injectieABX advanced biochemical compounds, Biomedizinische Forschungsreagenzien GmbH
- SwitzerlandSWAN-PSMA-1007 1 ml / 10 ml, InjektionslösungSWAN Isotopen AG SWAN Haus, Inselspital
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/91cf1da3-1733-4dc9-9c5c-6983bd9609b3 GET /v1/drugs/91cf1da3-1733-4dc9-9c5c-6983bd9609b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "1300 MBq/ml",
"packaging": "05909991564339 ¦ Lz ¦ 160306\n1 fiol. 15 ml\n05909991564346 ¦ Lz ¦ 160307\n1 fiol. 20 ml",
"substance": "PSMA-1007 (18F) solutio iniectabilis 1300 MBq/ml",
"common_name": "PSMA-1007 (18F) solutio iniectabilis",
"pl_product_id": "100474555",
"pozwolenie_nr": "28847",
"auth_procedure": "MRP",
"authorisation_validity": "2030-01-29"
}See everything about psma-1007 18f.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.